Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proxalutamide Treatment for COVID-19 ICU Patients
NCT04853927Phase 3Withdrawn
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Proxalutamide + SOC with Placebo + SOC (2 arms). Primary endpoint: Proportion of death at Day 28. Planned start Feb 2021; status: withdrawn.
02
Drugs
proxalutamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04853927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853927.